ZhongMei Consulting was founded on the vision of bringing Chinese life sciences innovation onto the global stage. China has traditionally been an importer of western goods and services, but we believe the Chinese healthcare industry is poised to become an exporter of biopharmaceutical intellectual property as well.

Globalization

In the beginning, developed economies import existing technologies and business models into the Chinese market.

 

The underlying philosophy is that the success factors that made the product successful in in the US or EU will be the same in China

 

Abbvie and Jaansen import， receive CFDA approval, and commercialize IMBRUVICA in Chinese markets

Localization

Once the product and brand is established, local customs and cultures are considered in order to better appeal to local Chinese customers.

 

The underlying philosophy is that the foreign product is sound, but slight tweaks to branding or administration may be needed

Chinese KOL’s recommend IMBRUVICA dosage stratification for certain Chinese patient populations

Domestic Innovation

As the product and brand continues to mature in China, innovations and improvements are made to augment or even replace the original product.

 

The underlying philosophy is that Chinese innovators know their market best, and should develop and implement improvements

Beigene runs clinical trials in China for a new BTK inhibitor with higher potency and selectivity

Reverse Innovation

As domestic innovation results in entirely new products, exporting Chinese technologies and products allows for global commercialization

 

The underlying philosophy is that the now locally developed Chinese product can compete and win globally against international products

Beigene gains FDA approval for marketing BRUKINSA in the United States

Who We Are

We are a boutique life science consulting and capital advisory firm that specializes in partnering with Chinese pharmaceutical and medical device companies to evaluate out-licensing opportunities for their products in the United States and in-licensing products from around the globe. We are a group of seasoned life science industry veterans with deep experience in US – China collaborations. While there are many companies that focus on representing Western pharmaceutical products into the domestic Chinese market, we are the only consulting firm that specializes in representing the Chinese pharmaceutical company in these transactions.

How We Work

We believe in the collaboration of American and Chinese professionals to advance lifesaving medicines from patients across the world. Our team and culture is structured to reflect that, combining decades of life science commercialization experience in the United States with a deep understanding of the Chinese healthcare industry and business culture.

职责

Kashif负责在美国的业务流程，也是在美国寻求合作或自行实现产品商业化的中国生命科学公司的重要思想伙伴。

专业领域

Kashif是生物制药和医疗设备行业的战略领导者，特别擅长为客户制定商业战略和上市准备计划。数十年来，他帮助客户通过内部或外部途径最大限度地发挥其临床资产的商业潜力。他既有支持大型跨国公司进行并购尽职调查的经历，也曾服务于新兴生物制药公司，帮助他们寻求战略合作或实现产品的商业化。

个人资历

Kashif曾在IQVIA（IMS咨询集团）担任上市准备工作的高级负责人，负责监督客户的商业战略发展，尤其关注新兴生物制药公司并为这些公司的首次商业上市或合作推广做准备。他还在Clarescent担任过十多年的董事总经理，这是一家专门从事生命科学行业市场研究和分析的专业咨询公司。

教育背景

Kashif 拥有美国西北大学凯洛格管理学院的MBA学位，以及约翰霍普金斯大学的电子工程学士学位。

角色

肖安东负责中国与非中国（美国、欧盟、日本等）客户之间的全部跨境合作和交易，并负责创建和促进全球工作流程。

专长

肖安东是广受生命科学公司和投资公司认可的战略思想伙伴。他专注为制药和生物技术公司、金融机构和学术研究机构提供咨询服务，并为之深耕15年。他擅长财务预测和交易支持，尤其善于为探索商业化方案的临床阶段公司提供宝贵建议。

 

肖安东擅长中美跨境交易和伙伴关系合作。他目前居住在香港，并经常往返于上海、旧金山湾区和纽约市。他拥有服务美国和中国客户的丰富经历，并了解两类客户在语言和文化上的细微差别。

从业经验

肖安东曾投身行业企业，也曾担任企业的外部顾问。此前，他是吉利德公司HIV 产品组合的HCP战略负责人，与多家咨询公司合作制定商业路线图并预测发展前景。肖安东还在IQVIA（原IMS咨询公司）和德勤咨询公司（原Monitor）担任过多年的战略顾问。肖安东也曾以顾问的角色与寻求在大中华地区实现资产商业化的数十家跨国公司、新兴生物制药公司和金融机构合作。

教育背景

肖安东获得哥伦比亚商学院的MBA学位，以及加利福尼亚大学戴维斯分校的药物化学学士学位。